- Previous Close
5.68 - Open
5.73 - Bid 5.71 x 200
- Ask 5.78 x 200
- Day's Range
5.64 - 5.87 - 52 Week Range
4.30 - 18.00 - Volume
48,857 - Avg. Volume
230,450 - Market Cap (intraday)
135.665M - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
-- - EPS (TTM)
-5.89 - Earnings Date Dec 20, 2024 - Dec 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.20
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
www.outlooktherapeutics.comRecent News: OTLK
View More
Performance Overview: OTLK
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OTLK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OTLK
View MoreValuation Measures
Market Cap
134.25M
Enterprise Value
134.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.69%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-94.05M
Diluted EPS (ttm)
-5.89
Balance Sheet and Cash Flow
Total Cash (mrq)
32.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-43.59M
Research Analysis: OTLK
View MoreCompany Insights: OTLK
OTLK does not have Company Insights